Clinical Trial Update: Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 results for onvansertib in combination with abiraterone and prednisone in adults with metastatic castration-resistant prostate cancer are reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abiraterone (abiraterone)
• Onvansertib (onvansertib)
• PREDNISONE (Prednisone)

Snippet

Sponsor: Cardiff Oncology | Conditions: Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-11-07